ORGO Q3 2024 Earnings — Organogenesis Holdings Inc. Revenue & Financial Results | Market Cap Arena

ORGOOrganogenesis Holdings Inc.

$355M

Q3 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$115M+6.1% YoY

Gross Profit

$88M76.7% margin

Operating Income

$6M5.4% margin

Net Income

$12M10.7% margin

EPS (Diluted)

$0.09

QoQ Revenue Growth

-11.6%

Cash Flow

Operating Cash Flow

$9M

Free Cash Flow

$6M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$446M

Total Liabilities

$168M

Stockholders' Equity

$279M

Cash & Equivalents

$94M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$115M	$109M	+6.1%
Gross Profit	$88M	$83M	+6.8%
Operating Income	$6M	$8M	-22.5%
Net Income	$12M	$3M	+289.4%

Revenue Segments

Advanced Wound care

$108M94%

Surgical and Sports Medicine

$7M6%